Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ
LOADING
|||
Switch Symbol:
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-36.11%
↓ 114% below average
Average (14q)
258.16%
Historical baseline
Range
High:2680.03%
Low:-92.55%
Volatility
1074.0%
High variability
| Period | Value |
|---|---|
| Q3 2025 | -36.11% |
| Q2 2025 | -35.40% |
| Q1 2025 | 8.47% |
| Q4 2024 | 95.96% |
| Q3 2024 | -37.41% |
| Q2 2024 | 99.31% |
| Q1 2024 | 74.18% |
| Q4 2023 | 48.03% |
| Q3 2023 | 1.24% |
| Q2 2023 | -92.55% |
| Q1 2023 | 2680.03% |
| Q4 2022 | 106.39% |
| Q3 2022 | -72.12% |
| Q2 2022 | 1032.33% |
| Q1 2022 | 0.00% |